GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Structure Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$22.01+0.93 (+4.41%)
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
Structure Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.57B | $163.01M |
| Enterprise Value | $226.83M | $86.72M |
| PB Ratio | 1.16 | 2.02 |
| P/TBV Ratio | 1.16 | 2.30 |
Income (trailing twelve months)
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$257.81M | -$21.44M |
| Pretax Income | -$214.13M | -$14.45M |
| Net Income | -$214.84M | -$22.46M |
| EBITDA | -$257.81M | -$16.91M |
| EPS (Diluted) | -$1.04 | -$0.83 |
Returns
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -20.2% | -53.1% |
| Return on Assets (ROA) | -19.2% | -41.0% |
| Return on Capital Employed (ROCE) | -19.0% | -37.8% |
Balance sheet
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.34B | $62.42M |
| Net Cash (Debt) | $1.34B | $15.68M |
| Net Cash Per Share | $6.28 | $0.66 |
| Equity (Book Value) | $1.35B | $48.79M |
| Book Value Per Share | $6.33 | $1.36 |
| Tangible Book Value | $1.35B | $23.06M |
| Working Capital | $1.31B | $75.77M |
Financial position
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 20.75 | 3.30 |
| Quick Ratio | 20.31 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$220.29M | -$12.35M |
| Capital Expenditures | -$4.21M | -$1.06M |
| Free Cash Flow | -$224.50M | -$20.28M |
| FCF Per Share | -$1.05 | -$0.42 |
Efficiency
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$976.52K | -$703.34K |
| Employee Count | 220 | 74 |
Dividends and yields
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -13.7% | -22.9% |
| FCF Yield | -14.3% | -9.15% |
Shares
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 213,930,000 | 58,179,650 |
| Shares Change (YoY) | 16.4% | 11.1% |
| Shares Change (QoQ) | 0.21% | 0.54% |
| Float | 208,079,000 | 49,173,100 |
| Shares Held by Insiders | 2.73% | 11.6% |
| Shares Held by Institutions | 31.6% | 59.4% |
Taxes
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Income Tax | $702.00K | $91.50K |
Scores
| Measure | Structure Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 13.12 | -0.28 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Structure Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.